Capricor Therapeutics Announces Proposed Public Offering of Common Stock

Core Viewpoint - Capricor Therapeutics has announced a proposed underwritten public offering of its common stock to support the development of its product candidates and general corporate purposes [1][2]. Group 1: Offering Details - The public offering includes a 30-day option for underwriters to purchase an additional 15% of the shares sold [1]. - The offering is subject to market conditions, and there is no assurance regarding its completion or terms [1]. - The securities are being offered under an effective shelf registration statement filed with the SEC [3]. Group 2: Use of Proceeds - The net proceeds from the offering will be used for the continued development and manufacturing of product candidates, working capital, and general corporate purposes [2]. Group 3: Company Overview - Capricor Therapeutics focuses on cell and exosome-based therapeutics for rare diseases, with its lead product candidate, deramiocel (CAP-1002), in Phase 3 clinical development for Duchenne muscular dystrophy [5]. - The company utilizes its proprietary StealthX™ platform for exosome technology aimed at various therapeutic applications [5]. - Capricor has an exclusive commercialization agreement for deramiocel in the U.S. and Japan with Nippon Shinyaku Co., Ltd., pending regulatory approval [8].